Complejo Hospitalario de Jaen

Running trials

• Not yet recruiting

  A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

  NCT07814417· Phase 2· Source

• Recruiting

  Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991· Phase 3· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain

  NCT06860945· Source

• Recruiting

  Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

  NCT06095583· Phase 3· Source

• Recruiting

  A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

  NCT05967689· Phase 2· Source

• Active, not recruiting

  A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV

  NCT06518408· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· Source

• Active, not recruiting

  Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

  NCT04090736· Phase 3· Source

• Active, not recruiting

  A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

  NCT03148418· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Metastatic breast cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• Colorectal cancer1 recruiting
• HIV1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen allergy

  2024-511383-88-00· Phase 2/3· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Source

• Completed

  ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

  NCT04245085· Phase 2· Source

• Terminated

  A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

  NCT04442126· Phase 1/2· Source

• Completed

  Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

  NCT04107727· Phase 2· Source

• Completed

  Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

  NCT03836066· Phase 2· Source

• Completed

  Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

  NCT03310957· Phase 1/2· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source